Cipla Ltd.

United States Food and Drug Administration (USFDA) has classified current Good Manufacturing Practices (cGMP) inspection conducted at Cipla’s manufacturing facility located in Bommasandra, Bengaluru as Voluntary Action Indicated (VAI). USFDA had conducted the inspection at said facility from May 26 to May 30, 2025.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.